ALBERT

Keywords: interstitial fibrosis ; lung ; alveolar fibroelastosis ; idiopathic pulmonary fibrosis ; pirfenidone ; nintedanib ; discontinuation ; body mass index ; adverse event ; antifibrotic treatment ; IPF ; alveolar epithelial cells ; intermediate epithelial cells ; transitional states ; LysoTracker ; flow cytometry ; lung transcriptomic profile ; CK5 ; NGFR ; CD24 ; epidermal growth factor ; epidermal growth factor receptor ; ErbB-signaling ; pulmonary fibrosis ; lung fibrosis ; tyrosine kinase inhibitor ; TGF-α ; TGF-β ; amphiregulin ; neuregulin 1 ; basal cells ; bronchial epithelium ; airway epithelium ; MUC5B ; single cell RNA sequencing ; epithelial populations ; antibody folding ; immunophilin ; interstitial lung disease ; ER stress ; tacrolimus ; FK506-binding protein ; peptidyl-prolyl isomerase ; 3D cultures ; IPF modelling ; drug screening ; idiopathic pulmonary fibrosis (IPF) ; histone deacetylase (HDAC) ; histone acetylation ; non-histone protein acetylation ; fibroblast-to-myofibroblast differentiation (FMD) ; type-II alveolar epithelial cell (AECII) ; bronchiolar basal cells ; bronchiolization ; Class I-HDAC-inhibitor ; (pan-)HDAC-inhibitor ; IGF1 ; IGF1R ; lung development ; bleomycin-induced pulmonary fibrosis ; bleomycin ; recombinant FGF10 ; alveolar epithelial progenitors ; AT2 cells ; n/a ; bic Book Industry Communication::M Medicine